Delivery Order 36F79720D0180-36C25526N0394
Award Date 8/5/26
Potential Completion Date 2/5/27
Potential Value $892K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
St. Louis, MO 63106, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Veterans Integrated Service Network 21 issued a $1.2 million delivery order to Novartis Pharmaceuticals Corporation on April 1, 2026, for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a radiopharmaceutical for metastatic castration-resistant prostate cancer, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The order is firm fixed price with place of performance at Mather, CA, and an ultimate completion date of September 30, 2026. No set-aside was used. The...
- Veterans Integrated Service Network 22 issued an $823,062.24 delivery order to Novartis Pharmaceuticals Corporation on July 20, 2026, for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a radiopharmaceutical for metastatic castration-resistant prostate cancer, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The FSS-61-IB is a General Services Administration-managed multiple-award federal supply schedule for pharmaceutical products serving the Department of Veterans...
- <p>Veterans Integrated Service Network 10 issued a $617,296.68 delivery order to Novartis Pharmaceuticals Corporation on July 1, 2026, for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a radiopharmaceutical cancer therapy for the Cleveland VAMC, with completion by December 31, 2026.</p> <p>The order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Place of performance is East Hanover, NJ 07936. This is a firm fixed-price delivery order with no set-aside.</p>
- Veterans Integrated Service Network 10 issued a $501,669.60 delivery order to Novartis Pharmaceuticals Corporation on January 5, 2026, for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a radiopharmaceutical for metastatic castration-resistant prostate cancer, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The Pharmaceuticals and Drugs FSS is a multi-vendor GSA schedule serving the federal government's pharmaceutical procurement needs. Place of performance is East...
- Novartis Pharmaceuticals Corporation received a $813,476.16 firm fixed-price delivery order from Veterans Integrated Service Network 2 (VISN 2) for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical cancer therapy product. The delivery order, issued on November 1, 2025, with an ultimate completion date of October 31, 2026, falls under Novartis' existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract vehicle. The place of performance is East...
- Novartis Pharmaceuticals Corporation received a delivery order award from Veterans Integrated Service Network 21 (VISN 21) for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical used in advanced cancer treatment. The delivery order, awarded October 1, 2025, carries a ceiling value of $1.63M and a firm fixed-price structure under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract has no small business set-aside designation, allowing...
- Veterans Integrated Service Network 21 issued a delivery order to Advanced Accelerator Applications USA Inc. on October 1, 2023, for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) prostate cancer treatment, with a ceiling value of $1,819,182.92. The order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) on a firm fixed-price basis. Place of performance is Millburn, NJ. The ultimate completion date is September 30, 2024. The award deobligates and closes out FY24...
- Novartis Pharmaceuticals Corporation received a $2.42M firm fixed-price delivery order from Veterans Integrated Service Network 10 (VISN 10) on February 1, 2026, for the supply of radiopharmaceuticals PLUVICTO (Lutetium Lu-177 Vipivotide Tetra) and LUTATHERA (Lutetium Lu-177 dotatate). The contract, which extends through December 31, 2026, will be performed in East Hanover, New Jersey, and was awarded without small business set-aside protections. This delivery order is issued under Novartis'...
- Novartis Pharmaceuticals Corporation was awarded a delivery order valued at $4.16M by Veterans Integrated Service Network 17 (VISN 17) for the supply of LU177 radiopharmaceutical products, specifically PLUVICTO (Lutetium Lu-177 Vipivotide Tetra) and LUTATHERA (Lutetium Lu-177 dotatate). The contract, issued on February 7, 2026, with completion targeted for February 6, 2027, operates under a firm fixed-price structure without small business set-aside designation. This delivery order is issued...
- The Defense Health Agency awarded a delivery order to Novartis Pharmaceuticals Corporation on October 1, 2024, for the supply of PLUVICTO (Lutetium Lu-177 Vipivotide Tetraxetan) and LUTATHERA (Lutetium Lu-177 dotatate), specialized radiopharmaceutical cancer therapies used in advanced oncology treatment. This fixed-price delivery order with economic price adjustment carries a ceiling value of $3.39M and is scheduled for completion by September 30, 2025. The order will be delivered to Fort Sam...